Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Cardiac failure+1

Recruiting

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ZILEBESIRAN

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Baxdrostat

Contact Research Centre

Cardiac failure

Recruiting

Registered drug

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bi 690517

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

HER2 positive breast cancer

Recruiting

Registered drugNo placebo

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Breast cancer+1

Recruiting

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Cardiac failure

Recruiting

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bi 690517

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Investigational

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:OMECAMTIV MECARBIL

Contact Research Centre

Breast cancer

Recruiting

Registered drug

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Inavolisib

Contact Research Centre

Hormone receptor positive breast cancer+2

Recruiting

Registered drugNo placebo

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Find therapies in clinical trials near you

27 trials match your criteria

Cardiac failure+1

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Cardiovascular disorder+1

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Cardiac failure

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Non-small cell lung cancer+1

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

HER2 positive breast cancer

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Breast cancer+1

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Cardiac failure

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Heart failure with reduced ejection fraction

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Breast cancer

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Hormone receptor positive breast cancer+2

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Triple negative breast cancer

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.